The proposed system is designed to: (1) enhance PROTAC solubility and membrane permeability, (2) improve tumor accumulation via EPR effect and GLUT1-mediated active targeting, (3) promote T-cell infiltration through GRh2-mediated collagen degradation, and (4) simultaneously induce tumor cell apoptosis and restore antitumor immunity via BRD4 degradation. The gene discussed is SLC2A1; the disease is neoplasm.